Trained scientist, currently working in BD, with deep expertise in business and clinical strategy with special interest in oncology and China BioPharma.
For those in the biotech industry who are interested in learning about how to do business development in China, my friend James Lee and I are hosting a webinar with BeiGene and I-Mab BD chiefs on Monday, December 2nd. https://t.co/mQ467NlEdP
Exciting to see more #ChinaBiotech thinking of #innovative#IO combinations. This might be the beginning of #ChinaBiopharma innovative combo deals vs rush to be #FIC or #BIC with single agents, which is not how the #ROW is thinking about #oncology https://t.co/Rqp6gOzZgN
Late-breaking additions to our CP panels, making them all the more stellar! Ian Somaiya, CFO, TCR2 Therapeutics and Iris Luo, MS, MBA Head of Business Development, North America, CStone Pharmaceuticals #CancerProgressNYC19#CancerResearch
Late-breaking additions to our CP panels, making them all the more stellar! Ian Somaiya, CFO, TCR2 Therapeutics and Iris Luo, MS, MBA Head of Business Development, North America, CStone Pharmaceuticals #CancerProgressNYC19#CancerResearch
Anti-PD-1/L1 pricing in China could affect the global market and influence how small-cap biotechs gain market share in the US #IO#oncology#ChinaBiotech#pricewar
https://t.co/qfQtTHUiHr
Amazing dynamics of how PD-1 antibodies are playing out with their pricing, subsequent affect #marketaccess while China continues to adjust their #reimbursement schemes, #BigPharma is entering a market that they will run into issues in competing #ChinaBiotech#oncology
PD-1 pricing in China (domestics vs $MRK $BMY) is 1 to watch. Next step: Further cuts for NRDL reimbursement? -> Report: China’s Innovent prices domestic PD-1 inhibitor at smaller discount than Junshi https://t.co/n80O7AHsvI via @BioCentury
That is very true, #ChinaBiotech is doing great and there may be real reasons two of those companies might had lost value. It is a market after all. #HKEX
First impressions are very hard to shake. Even today when stories are written they say the HK biotech expedient is off to a rocky start. All b/c of one company (the first) Ascletis. The reality is that it is off to a great start, with the natural volatility that comes w/ biotech.
CStone starts trading today as 2616. The IPO price is HK$12.
Here's the list of HK bio listings then and now (HK$):
AppTec $68 -> $85.55
Junshi $19.38 -> $21.85
Innovent $13.98 -> $24.05
Hua $8.28 -> $8.56
BeiGene $108 -> $83.90
Ascletis $14 -> $6.80
Great article about #HKEX and expectations in reducing valuations of #prerevenuebiotech#ChinaBiotech and how having a diversified investor base is a good thing
.@HKEXGroup CEO Charles Li sits down with BioCentury to discuss the state of China's budding biotech sector and the exchange's role in connecting East to West. https://t.co/gKSnk9Dp9q
This pipeline is not that exciting, money is still flowing into #ChinaBiotech, I hope future investments will be more aligned with #innovation, not a lead that is a #reformulation
$PFE being very innovative with their #payforperformance use of #Ibrance for #breastcancer in China. Why is this not being established in other countries? https://t.co/AeWf9CdScr
@AndyBiotech But have to be aware, a lot of patients are dead after the first 2 lines of therapy, keeping them alive with this drug for a prolonged time is a successful endpoint #pancreaticcancer
$BGNE is really going after the best in class #BIC argument for their assets and making strong cases with clinical data. Bravo to their R&D team! #oncology#ChinaBiotech